Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Assets (2016 - 2025)

Historic Assets for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $9.7 million.

  • Pharma's Assets fell 603.72% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 603.72%. This contributed to the annual value of $8.7 million for FY2025, which is 1166.43% down from last year.
  • Latest data reveals that Pharma reported Assets of $9.7 million as of Q3 2025, which was down 603.72% from $7.9 million recorded in Q2 2025.
  • Over the past 5 years, Pharma's Assets peaked at $35.9 million during Q1 2021, and registered a low of $7.9 million during Q2 2025.
  • For the 5-year period, Pharma's Assets averaged around $18.7 million, with its median value being $16.5 million (2023).
  • In the last 5 years, Pharma's Assets soared by 2948.72% in 2021 and then plummeted by 4390.13% in 2023.
  • Quarter analysis of 5 years shows Pharma's Assets stood at $31.3 million in 2021, then crashed by 35.85% to $20.1 million in 2022, then tumbled by 43.9% to $11.3 million in 2023, then dropped by 19.37% to $9.1 million in 2024, then grew by 7.33% to $9.7 million in 2025.
  • Its Assets stands at $9.7 million for Q3 2025, versus $7.9 million for Q2 2025 and $8.7 million for Q1 2025.